drugset

drugset / Trial / NCT05676034

AMX0035 in Adult Patients With Wolfram Syndrome

NCT05676034 ↗

Phase 2 Active not recruiting 12 enrolled Amylyx Pharmaceuticals Inc.

NaSingle-groupOpen-labelTreatment

Summary

This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome.

Timeline

Start: 2023-03-03
Primary completion: 2024-07-23
Completion: 2028-05-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AMX0035	Unknown	—	Oral

Indications